MedTrace Logo

Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects

NCT03485885 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2019-01-10

No results posted yet for this study

Summary

The aim of the present study is to describe the bioavailability for the proprietary standardized maqui berry extracts Delphinol® and MaquiBright® enriched in anthocyanins and in particular delphinidins. The analyses are based on two selected key substances namely delphinidin-3-glucoside and cyanidin-3-sambubioside and their metabolism to phenolic acids.

The bioavailability of anthocyanins specific for Delphinol®/MaquiBright® was analyzed in plasma sample kinetics (at 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h and 8h after intake of 1000mg standardized maqui berry extract in capsules) in 12 healthy subjects.

Conditions

  • Bioavailability

Interventions

DIETARY_SUPPLEMENT

Standardized maqui berry extract enriched in anthocyanins

Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules - 250mg each) with 200ml still water

Sponsors & Collaborators

  • BioTeSys GmbH

    collaborator OTHER

  • Anklam Extrakt

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-23
Primary Completion
2017-12-12
Completion
2017-12-12

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03485885 on ClinicalTrials.gov